Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same

A technology of hepatocellular carcinoma and cancer stem cells, which is applied in the field of personalized high-purity hepatocellular carcinoma stem cells, said stem cells and their uses, and can solve problems such as adverse effects, influence, and tumor resistance of patients

Inactive Publication Date: 2016-02-03
NEOSTEM ONCOLOGY
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Fourth, it may be responsible for tumor resistance to chemotherapy or radiotherapy
Specific antigen-targeted therapies (such as anti-CD133, ant...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
  • Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
  • Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0178] Isolation and Expansion of HCC Cancer Stem Cells from Needle Aspiration Biopsy

[0179] Hepatocellular carcinoma (HCC) tumor samples are histologically heterogeneous, consisting of more or less differentiated cancer cells as well as normal parenchymal, stromal, and vascular cells. The aim of the method presented here is to isolate and expand populations of cancer stem cells derived from smaller HCC samples. In addition, these cells are used to prepare autologous therapies for the treatment of HCC and the prevention of HCC recurrence.

[0180] Procedures and reagents are designed to maintain typical stem cells without maintaining the in vitro persistence / proliferation of differentiated hepatocytes, biliary epithelial cells, vascular endothelial cells, smooth muscle cells or fibroblasts. Typical components described in the literature, such as corticosteroids and serum, are omitted; instead, a basal medium formulation with specific ratios of amino acids and vitamins sup...

Embodiment 2

[0193] Generation of Loaded Dendritic Cell Compositions

[0194] The source of antigens is autologous tumor cells derived from continuously proliferating self-regenerative cells derived from fresh tumor tissue of the patient. These cells have the characteristics of cancer stem cells. At all times in the surgical and lesion setting, biopsies were handled with strict adherence to a sterile protocol to ensure that the specimens were sterile.

[0195] A pathologist obtains fresh tissue from a biopsy of a patient's tumor. Using a sterile scalpel and forceps, the samples were cut into 10 mm sections and transferred to transport tubes containing transport medium, processed promptly to avoid drying of the samples. Samples were shipped to the manufacturing facility by overnight courier within 48 days of surgical resection.

[0196] In the manufacturing facility, samples were dissociated into single cell suspensions in a clean room and placed in cell culture conditions designed to ...

Embodiment 3

[0201] Phase I trial of active-specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma

[0202] Because micrometastatic disease is undetectable at diagnosis, HCC is rarely cured with standard therapies. In addition, HCC is often associated with hepatitis B virus (HBV) infection, which renders patients ineligible for liver transplantation. Active specific immunotherapy (ASI) using autologous dendritic cells loaded with antigens derived from autologous tumor stem cells has been associated with promising long-term survival outcomes in patients with metastatic melanoma, although data from those trials Patients with HBV were excluded. This ASI approach deserves evaluation in other tumor types, including HCC. Surgical resection is part of standard therapy for many patients, thereby providing a tumor source for the generation of autologous tumor cell lines. Although A...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The disclosure provides cancer stem cells, for use in stimulating immune response against a cancer, such as hepatocellular carcinoma (HCC). Methods for preparing and purifying the cancer stem cells are provided.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Provisional Patent Application 61 / 774,517, filed March 7, 2013, under 35 U.S.C. § 119(e). This application is also a continuation-in-part of International Application PCT / US2013 / 053850, filed August 6, 2013, which requires U.S. Provisional Patent Application 61, filed August 15, 2012, under 35 U.S.C. §119(e) / 683,477 and U.S. Provisional Patent Application 61 / 718,643, filed October 25, 2012. The entire content of said application is incorporated herein by reference. technical field [0003] The present invention relates to hepatocellular carcinoma stem cells, immunogenic compositions derived from said stem cells, and methods of making and using said stem cells. Background technique [0004] In solid tumors, a smaller percentage of cells has the capacity to initiate tumors with the same histological heterogeneity as the parental tumor. These cells are known as cancer stem ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N5/0784C12N5/095
CPCA61K35/13A61K35/15A61K38/193A61K2039/5154A61K2039/5158A61P1/16A61P35/00A61P37/04C12N5/0639C12N5/0695C12N2500/90C12N2501/727A61K2300/00
Inventor N.贾布里尔C.T.弗里德里克森A.科恩富思
Owner NEOSTEM ONCOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap